Comparative Pharmacology
Head-to-head clinical analysis: XYLOCAINE 1 5 W DEXTROSE 7 5 versus XYLOCAINE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: XYLOCAINE 1 5 W DEXTROSE 7 5 versus XYLOCAINE PRESERVATIVE FREE.
XYLOCAINE 1.5% W/ DEXTROSE 7.5% vs XYLOCAINE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that blocks sodium channels, thereby inhibiting the propagation of action potentials in peripheral nerves, leading to local anesthesia.
Lidocaine stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking impulse initiation and conduction. It binds to voltage-gated sodium channels in the inactivated state, preventing depolarization and propagation of action potentials.
Spinal anesthesia: 1.5-2 mL (22.5-30 mg lidocaine) for lower extremity or perineal procedures; 2-3 mL (30-45 mg) for lower abdominal or urological procedures. Administered via lumbar puncture.
Adult dose: 1-30 mL of 1% or 2% solution (10-600 mg) via subcutaneous infiltration, peripheral nerve block, or epidural; max 4.5 mg/kg (300 mg without epinephrine, 7 mg/kg [500 mg] with epinephrine) per 2-hour period.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in adults with normal hepatic function; may be prolonged to 3–5 hours in patients with hepatic impairment or congestive heart failure.
Terminal elimination half-life approximately 1.5-2 hours in adults; prolonged in hepatic impairment (up to 3-4 hours) and congestive heart failure.
Renal excretion of metabolites (predominantly 4-hydroxy-2,6-xylidine and conjugates) accounts for >80% of elimination; less than 10% eliminated unchanged in urine. Biliary/fecal excretion of metabolites contributes <10%.
Renal excretion of metabolites (90-95% as metabolites, <5% unchanged); biliary/fecal excretion minimal (<1%).
Category C
Category C
Local Anesthetic
Local Anesthetic